Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-22-087042
Filing Date
2022-08-08
Accepted
2022-08-08 12:18:48
Documents
1
Group Members
DECHENG CAPITAL MANAGEMENT II (CAYMAN), LLCXIANGMIN CUI

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G tm2222772d1_sc13g.htm SC 13G 68428
  Complete submission text file 0001104659-22-087042.txt   70249
Mailing Address MAPLES CORPORATE SERVICES, UGLAND HOUSE PO BOX 309, SOUTH CHURCH ST, GEORGE TOWN GRAND CAYMAN E9 KY1-1104
Business Address MAPLES CORPORATE SERVICES, UGLAND HOUSE PO BOX 309, SOUTH CHURCH ST, GEORGE TOWN GRAND CAYMAN E9 KY1-1104 345-949-8066
Decheng Capital China Life Sciences USD Fund II, L.P. (Filed by) CIK: 0001650291 (see all company filings)

EIN.: 981257397 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 75 SHOREWAY ROAD, SUITE C SAN CARLOS CA 94070
Business Address 75 SHOREWAY ROAD, SUITE C SAN CARLOS CA 94070 650.931.6236
Apexigen, Inc. (Subject) CIK: 0001814140 (see all company filings)

EIN.: 851260244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-92133 | Film No.: 221143407
SIC: 2834 Pharmaceutical Preparations